Background: Acquired lymphedema is a common consequence of cancer surgery. Fibrosis is one of the main causes of chronic lymphedema since it hinders lymphatic regeneration and this causes a significant decrease in lymphatic flow and accumulation of excessive protein-rich fluid. The transforming growth factor-β1 (TGF-β1) signaling pathway is known in a process of wound repair and fibrosis. In our study, the purpose was to evaluate the efficacy of EW-7197, a peroral TGF-β type I receptor kinase inhibitor, in treating acquired lymphedema.

中文翻译：

---

EW-7197 是一种转化生长因子 - β I 型受体激酶抑制剂，可改善小鼠尾部模型中的获得性淋巴水肿。

背景：获得性淋巴水肿是癌症手术的常见后果。纤维化是慢性淋巴水肿的主要原因之一，因为它会阻碍淋巴再生，这会导致淋巴流量显着减少和过多富含蛋白质的液体积聚。转化生长因子-β1 (TGF-β1) 信号通路在伤口修复和纤维化过程中是已知的。在我们的研究中，目的是评估 EW-7197（一种口服 TGF-β I 型受体激酶抑制剂）治疗获得性淋巴水肿的功效。